Pharmacyclics Inc (PCYC.OQ)

PCYC.OQ on NASDAQ Stock Exchange Global Select Market

254.51USD
1 May 2015
Change (% chg)

$-1.69 (-0.66%)
Prev Close
$256.20
Open
$256.29
Day's High
$256.49
Day's Low
$254.02
Volume
358,207
Avg. Vol
419,625
52-wk High
$260.31
52-wk Low
$82.56

PCYC.OQ

Chart for PCYC.OQ

About

Pharmacyclics, Inc. is a United States-based biopharmaceutical company engaged in developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.  The Company designs, develops and commercializes therapies intended to improve quality of life, increase duration of life and resolve... (more)

Overall

Beta: 0.66
Market Cap(Mil.): $19,617.19
Shares Outstanding(Mil.): 76.79
Dividend: --
Yield (%): --

Financials

  PCYC.OQ Industry Sector
P/E (TTM): 237.34 188.47 40.23
EPS (TTM): 1.08 -- --
ROI: 11.13 -0.64 15.26
ROE: 11.82 -2.50 16.08
Search Stocks

Pharmacyclics cancer drug successful as combination therapy: independent panel

- An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful against two similar forms of cancer in combination with other drugs.

16 Mar 2015

UPDATE 1-Pharmacyclics cancer drug successful as combination therapy - independent panel

March 16 - An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful against two similar forms of cancer in combination with other drugs.

16 Mar 2015

CORRECTED-Independent panel recommends unblinding study after Imbruvica shows clear benefit

March 16 - An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful in treating two types of cancer in combination with other drugs.

16 Mar 2015

AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal

- AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. | Video

05 Mar 2015

AbbVie CEO defends Pharmacyclics deal to skeptical investors

NEW YORK - AbbVie Inc chief Richard Gonzalez fought two other drugmakers to "the bitter end" to buy Pharmacyclics Inc for its hot-selling Imbruvica cancer drug, but may have a harder time convincing investors it is worth $21 billion.

05 Mar 2015

UPDATE 1-AbbVie CEO defends Pharmacyclics deal to skeptical investors

NEW YORK, March 5 - AbbVie Inc chief Richard Gonzalez fought two other drugmakers to "the bitter end" to buy Pharmacyclics Inc for its hot-selling Imbruvica cancer drug, but may have a harder time convincing investors it is worth $21 billion.

05 Mar 2015

US STOCKS-Wall St closes up slightly ahead of jobs report

* Indexes up: Dow 0.21 pct, S&P 0.12 pct, Nasdaq 0.32 pct (Updates to afternoon, adds commentary)

05 Mar 2015

US STOCKS-Wall St up slightly ahead of jobs report

* Indexes up: Dow 0.2 pct, S&P 0.18 pct, Nasdaq 0.39 pct (Updates to afternoon, adds commentary)

05 Mar 2015

UPDATE 4-AbbVie boosts cancer drug pipeline with $21 bln Pharmacyclics deal

* Deal cuts reliance on Humira; expected to close mid 2015 (Adds Breakingviews link)

05 Mar 2015

Biotech buys get pharma M&A off to flying start in 2015

LONDON - AbbVie's $21 billion deal to buy Pharmacyclics shows big pharma's hunger for new drugs at a time when research at smaller biotechnology companies is driving some of the most promising advances in medicine. | Video

05 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks